QXO heads into its May 8 earnings call with short sellers at their most aggressive in months — and the stock already down 4% on the week.
Short interest has become the dominant story. At 13.1% of the free float, it has nearly doubled from the ~9% level that held steady through late March and early April. The acceleration has been relentless: up 43% in one month and up almost 9% in the past week alone, with 94 million shares now estimated short. That is not a crowded position in absolute terms for some names — but for a stock priced at $18.87 and facing a known catalyst in two days, the pace of accumulation stands out sharply.
The borrow market tells a more nuanced story. Cost to borrow reached a local peak of 5.5% on April 23, nearly eleven times the sub-0.5% rate that prevailed through most of March and early April. It has since come down to 2.3%, easing roughly 46% over the past week — but the retreat follows a surge, not a reversal of the underlying thesis. Availability is tighter than most of the year, with the lending pool meaningfully consumed. The one-month borrow cost is still up 363% versus where it was. Shorts are not backing away; they are simply borrowing at a somewhat cheaper rate after last week's spike. Options positioning reinforces the caution: the put/call ratio has climbed to 0.62, running above its 20-day average of 0.51 and close to 1.1 standard deviations above the norm. That is not extreme by itself, but it aligns with the short-selling pattern — both signals point toward investors adding downside exposure into the print.
The Street is broadly constructive, but not without reservations. Oppenheimer raised its target to $32 last week, while Keybanc did the same earlier in April — both maintaining positive ratings. RBC Capital moved the other way in early April, trimming to $28 from $30 while holding its Outperform. The mean analyst target of $32.69 implies roughly 73% upside from current levels, which is a wide gap reflecting genuine disagreement about the timeline for value realisation. Bulls point to the pending TopBuild acquisition as a highly accretive deal with meaningful synergies and the potential to make QXO a tech-enabled leader in building products distribution. Bears flag the housing market headwinds, declining organic estimates for the first half of the year, and the concern that heavy investment spending compresses near-term profitability. The ORTEX short score has drifted higher throughout April and now sits at 78.9 — near the top of the range over the past year.
Earnings history adds important context here. QXO's last three reported results all produced negative reactions: the stock fell 4%, 5%, and 3% on the day following each print, with five-day moves of -8.7%, -7.5%, and -2.9% respectively. That is a consistent pattern of post-earnings weakness, and it explains why short sellers have accelerated ahead of the May 8 event. The company did file a prospectus to facilitate shareholder resales in late April, which may have added additional supply concerns to the mix.
Institutionally, Morgan Stanley Investment Management added more than 11.5 million shares in Q1 2026, now holding nearly 8% of the company. Fred Alger also built a notable position. Against that backdrop, the short position is being absorbed by buyers — but the balance of pre-earnings positioning is clearly tilted toward caution. The question heading into Thursday is whether the Q1 print and any updated guidance on the TopBuild integration can shift that balance.
See the live data behind this article on ORTEX.
Open QXO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
